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Abstract
Compared to the general population, HIV-infected patients are at higher risk of developing
non-AIDS-defining cancers. Chronic HCV infection has also been associated with a higher
risk than that of the general population of developing cancers other than hepatocarcinoma.
Evaluation of the impact of HCV-related factors on non-AIDS-defining and non HCV-liver
(NANL) related cancers among HIV/HCV co-infected patients are scarce. The aim of this
study was to identify the impact of HIV/HCV clinical characteristics on NANL related cancers
in a large cohort of HIV/HCV-coinfected patients followed from 2005 to 2017. Cox propor-
tional hazards models with delayed entry were used to estimate factors associated with
NANL related cancer. Among 1391 patients followed for a median of 5 years, 60 patients
developed NANL related cancers, yielding an incidence rate of 8.9 per 1000 person-years
(95% CI, [6.6–11.1]). By final multivariable analysis, after adjustment for sex, tobacco or
alcohol consumption, baseline CD4 cell count and HCV sustained viral response (SVR),
age and a longer duration since HIV diagnosis were independently associated with a
higher risk of NANL related cancer (aHR for each additional year 1.10, 95% CI 1.06–1.14,
p<0.0001 and 1.06, 95% CI 1.01–1.11, p = 0.02, respectively). Duration of HCV infection,
cirrhosis, HCV viral load, genotype and SVR were not associated with the occurrence
of NANL related cancer. Among HIV/HCV-coinfected patients, age and the duration of
HIV infection were the only characteristics found to be associated with the occurrence of
NANL related cancer. In contrast, no association was observed with any HCV-related
variables.
Introduction
HIV-infected patients have a higher risk of developing non-AIDS-defining cancers compared
to the general population [1–4]. Age, duration of HIV infection and immune status are known
risk factors for many of these non-AIDS cancers [2,5,6]. Additional factors may vary by cancer,
such as poor immune control for oncogenic viruses such as Human papillomavirus (HPV) or
Epstein Barr virus (EBV), and/or lifestyle choices, such as tobacco or alcohol use for lung or
digestive cancers [2,4]. HCV is an oncogenic virus proven to cause hepatocarcinoma (HCC)
and B-cell non-Hodgkin lymphoma [7,8]. Furthermore, some epidemiological studies suggest
that patients with chronic HCV infection are also at higher risk than the general population of
developing other cancers, such as cancers of the esophagus, pancreas, prostate, thyroid, breast
or oral cavity [5,7,9–11]. In national surveys consecutively conducted in France in 2000, 2005
and in 2010, the rate of death attributed to non-AIDS-defining cancers and non HCV-liver
(NANL) related cancers significantly increased between 2000 and 2010 (11% of deaths in 2000,
17% in 2005 and 22% in 2010, p<0.001) [12].
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Evaluations of factors associated with NANL related cancers among HIV/HCV co-infected
patients are scarce. In particular, the influence of HCV-related factors, such as duration of
HCV infection, cirrhosis, HCV genotype and HCV viral load, needs further study. We aimed
to investigate the associations between HIV/HCV clinical characteristics, and patients’ socio-
behavioural profiles, and the occurrence of NANL related cancers in a large cohort of HIV/
HCV-coinfected patients (ANRS CO13 HEPAVIH) followed in the era of increasing effective-
ness of combination antiretroviral therapy (cART).
Methods
This study involved HIV/HCV coinfected patients enrolled in the ANRS CO13 HEPAVIH
cohort, a prospective, hospital-based cohort of HIV/HCV coinfected patients created in 2005
and involving 28 hospitals in France [13]. For this study, patients with at least one follow-up
visit before 31st September 2017 were included. Patients with a history of cancer at inclusion,
patients with spontaneously cured HCV, those without follow-up, and those with missing data
for tobacco consumption, alcohol consumption or cirrhotic status were excluded. The study
was approved by the institutional review board: Comite´ Ile de France 3, file n˚2234, ref CG/
LG/CC 2005-255. Each participant agreed to participate to the ANRS CO13 Hepavih cohort
by written consent.
The primary outcome was the time to occurrence of a first NANL related cancer. Cancer
cases were prospectively collected. Patients with cancers were identified using the medical dic-
tionary for regulatory activities (MedDRA). Cancer cases were also researched in the record
deaths mentioning the cause of death. Patients were censored at the date of the diagnosis of a
first NANL related cancer, at their date of death, or at their last follow-up, date whichever
came first.
Qualitative variables were described as number (percentage) and quantitative variables as
median (interquartile range [IQR]). Independent risk factors associated with NANL related
cancer were studied using survival analysis. To take into account competitive risk for death
without NANL related cancer, patients were censored at their death date if they didn’t experi-
ence a NANL cancer before.
First, univariable Cox proportional hazards models were used to identify factors associated
with NANL related cancers. Variables included in these models were: age at inclusion (in
years), sex, smoking status (never, former, current), alcohol consumption (never, former, cur-
rent), time since HIV diagnosis (in years), duration of antiretroviral treatment (in years),
AIDS status (yes, no), CD4 cell count nadir inferior to 200 cells/mm3 (yes, no), CD4 cell count
(in cells/mm3), CD8 cell count (in cells/mm3), CD4/CD8 ratio, HIV viral load undetectable
(yes, no), HCV transmission group (men who have sex with men, intravenous drug users, oth-
ers), duration of HCV infection (counting from the date of the first transfusion, the date of ini-
tial intravenous drug use, or the first positive HCV serology in subjects who were infected via
the sexual route and who did not develop acute hepatitis C), HCV genotype 1 (yes, no). Sus-
tained viral response (SVR) to anti-HCV therapy (yes, no) defined as an undetectable serum
HCV RNA (< 15 IU per milliliter) 24 weeks after treatment completion was included in the
models as a time dependent variable. Cirrhosis status assessed by transient elastometry (TE) or
FIB-4 score calculated as previously described [14] for patients without liver stiffness measure-
ment. Cut-offs defining fibrosis were liver stiffness measurement superior or equal to 12.5 kPa
and FIB-4 superior or equal to 3.45. Type 2 diabetes (yes, no) defined by a preexisting diagno-
sis of diabetes or an antidiabetic treatment at baseline, or a fasting blood glucose value of�7
mmol/L at least twice during follow-up. Wald’s tests were realized, and p-values were
estimated.
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Then a manual backward elimination procedure was realized in a Cox proportional hazards
model. Variables with p-value inferior to 0.25 in univariate analysis were included in the
model and factors a priori deemed to be important predictive factors of NANL cancers (age,
sex, tobacco consumption, alcohol consumption, CD4 cell count and SVR) were forced in the
model. Then variables not a priori important and with p-values superior to 0.05 were excluded
from the model. The proportional hazards assumption was tested with interactions between
covariates and time.
Cumulative incidences of NANL cancer were estimated for each quartile of time since HIV
diagnosis using Aalen Johansen methodology to take into account competitive risk of death
without NANL related cancer. All statistical tests were two-sided, with a type I error of 5%. Sta-
tistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North
Carolina).
Results
Among 1427 eligible patients, 36 were excluded due to missing data for tobacco-, alcohol-con-
sumption or cirrhosis status. Therefore, a total of 1391 patients were considered for this
analysis.
The demographic and clinical characteristics of the study population at baseline are shown
in Table 1. Most patients were male (73%), and median age was 46 years (IQR, 43–51 years).
There were respectively 69% current smokers and 49% current alcohol drinkers. The median
time since HIV diagnosis was 18.6 years (IQR, 13.9–21.5). Most patients (90%) received cART,
and the median duration of cART was 129 months (IQR, 82–179). AIDS was present in 25%
of patients. The median CD4 cell count was 478 cells/mm3 (IQR, 325–675 cells/mm3), median
CD4 cell count nadir was 155 cells/mm3 (IQR, 73–248 cells/mm3), and 75% of patients had an
undetectable HIV viral load (<50 copies/ml). At baseline, 1173 patients (96%) had a positive
HCV RNA and 27% had cirrhosis. The median duration of HCV infection was 14 years (IQR,
8.0–22).
Median follow-up was 5 years (IQR, 1.9–7.5 years). Overall, 94 patients developed cancers,
7 AIDS defining cancers, 27 HCV related cancers and 60 NANL related cancers. Median
time between cohort inclusion and cancer diagnosis was 2.7 years (IQR, 1.3–5.3). The inci-
dence rate of NANL related cancers was 8.9 per 1000 person-years (95% CI, [6.6–11.1]).
Median age at cancer diagnosis was 52 (IQR, 48–56) years. The types of these cancers are
described in Table 2. The results of any search for HPV through histological reports were not
available in our cohort. However, 9 patients (15%) had a high probability of HPV-related
cancers (anal cancer n = 6, tonsil cancer n = 1, tongue cancer n = 1, penile cancer n = 1). Five
patients (8.3%) had EBV related cancers (Hodgkin lymphoma in all). Non-melanoma skin
cancers and lung cancers were the most frequent NANL related cancers with respectively 13
and 14 cases.
By univariable analysis, the following variables were related to the outcome with a p-value
<0.25: age at baseline (HR = 1.09, 95% CI [1.05–1.15], p<0.0001) and duration since HIV
diagnosis (HR = 1.06, 95% CI [1.01–1.13], p = 0.0281). Duration of cART, CD4 cell count
nadir below 200/mm3 and duration of HCV infection tended to be associated with an increas-
ing risk of NANL cancers while CD8 cells count tended to be associated with a decreasing risk.
These factors were included in the multivariable analysis in addition to sex, tobacco, alcohol,
CD4 cell count and SVR which forced in the model. Only age and a longer duration since HIV
diagnosis remained independently associated with a higher risk for NANL related cancer
(adjusted HR 1.10 for each additional year, 95% CI 1.06–1.14, p<0.0001 and adjusted HR 1.06
for each additional year, 95% CI 1.01–1.11, p = 0.02, respectively). SVR tended to decrease the
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risk of NANL related cancer but the association was not statistically significant (adjusted HR
0.71, 95% CI 0.21–2.32, p = 0.56) (Table 3).
Discussion
In this large prospective cohort of HIV/HCV-coinfected patients followed between 2005 and
2017, 60 patients developed NANL related cancers. Over this period of increasing effectiveness
of cART, the overall incidence of NANL related cancers was 8.9 per 1000 person-years. In
Table 1. Baseline characteristics of the 1391 HIV/HCV-coinfected patients from the ANRS CO13 HEPAVIH
cohort; results are medians (IQR) or numbers (%).
Total (n = 1391)
Age (years) 46 (43–51)
Males 1009 (73)
Smoking status
• Never 190 (13.6)
• Current 954 (68.6)
• Former 247 (17.8)
Alcohol consumption�
• Never 306 (22)
• Current 682 (49)
• Former 403 (29)
HIV infection
Time since HIV diagnosis (years) 18.6 (13.9–21.5)
AIDS 348 (25.3)
Ongoing antiretroviral treatment 1255 (90.4)
Duration of antiretroviral treatment (months) �� 129.2 (82.4–178.7)
CD4 cell nadir (/mm3) 155 (73–248)
CD4 cell nadir <200(/mm3) 799 (62.6)
Absolute CD4 cell count (/mm3) 478 (325–675)
Absolute CD8 cell count (/mm3) 787 (546–1084)
CD4/CD8 ratio 0.6 (0.4–0.9)
HIV viral load < 50 copies/ml 1038 (74.8)
HCV infection
HCV transmission group
• MSM��� 92 (7.6)
• Intravenous drug users 807 (66.8)
• Others 310 (25.6)
Duration of HCV infection (years) 14 (8–22)
HCV treatment-naïve patients 933 (67.1)
HCV genotype 1 750 (56.7)
Positive serum HCV RNA 1173 (96.2)
Cirrhosis 378 (27.2)
HCV viral load, log10 IU/mL 6.2 (5.6–6.6)
Diabetes 86 (6.2)
HBs antigen positivity 33 (2.4)
�>50 g/daily for men; >30 g/daily for women;
�� zero in patients not receiving antiretroviral therapy;
���: Men who have sex with men
https://doi.org/10.1371/journal.pone.0208657.t001
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keeping with previous reports showing that the most important risk factors for non-AIDS-
defining cancers were advancing age and the duration of HIV infection, age and the time since
HIV diagnosis, after adjustment for other factors, were the only factors found to be indepen-
dently associated with a higher risk of developing NANL related cancers in our study [2].
Table 2. The 60 non-AIDS-defining cancers and non HCV-liver related cancers diagnosed in HIV/HCV-coin-
fected patients.
Type of Cancer Number of patients
Nasopharynx/Tongue/Tonsil cancer 6 (10)
Lung cancer 14 (23)
Anal cancer 6 (10)
Esophagus/colon/rectal/pancreas cancer 6 (10)
Breast or ovarian cancer 2 (3)
Hodgkin’s lymphoma 5 (8)
Non-melanoma skin cancer 13 (22)
Renal/urethra/prostate/penile cancer 5 (8)
Others 3 (5)
https://doi.org/10.1371/journal.pone.0208657.t002
Table 3. Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers among HIV/HCV-coinfected patients—Univariate and multivariate
analyses from the ANRS CO13 HEPAVIH Cohort (N = 1391).
Univariable analysis Multivariable analysis
RR [95% CI] P RR [95% CI] P
Age 1.09 [1.05–1.14] <0.0001 1.10 [1.06–1.14] <0.0001
Female (versus Male) 0.84 [0.43–1.66] 0.61 0.79 [0.41–1.51] 0.43
Smoking status (versus never) 0.27 0.08
• Former 1.67 [0.42–6.68] 1.08 [0.34–3.45]
• Current 2.40 [0.74–7.81] 2.22 [0.84–5.85]
Alcohol consumption (versus never) 0.79 0.56
• Former 0.78[0.35–1.74] 0.66 [0.31–1.40]
• Current 0.81 [0.40–1.64] 0.79 [0.41–1.51]
Time since HIV diagnosis (years) 1.06 [1.01–1.13] 0.028 1.06 [1.01–1.11] 0.026
AIDS status 0.99 [0.50–1.96] 0.98
Duration of ARV1 treatment (months) 1.00 [1.00–1.01] 0.066
CD4 cell count nadir<200 cell/mm3) 1.62 [0.82–3.21] 0.16
CD4 cell count (/mm3)2 1.00 [0.95–1.05] 0.98 0.98 [0.94–1.03] 0.46
CD8 cell count (/mm3) 2 0.98 [0.95–1.01] 0.19
CD4/CD8 ratio 1.05 [0.53–2.10] 0.88
Undetectable HIV RNA viral load 0.88 [0.47–1.65] 0.67
HCV infection group (vs MSM) 0.65
• Intravenous drug users 1.46 [0.35–6.08]
• Others 1.09 [0.24–4.97]
Duration of HCV infection (years) 1.03 [0.99–1.07] 0.13
HCV genotype 1 versus others 0.97 [0.54–1.75] 0.91
HCV sustained viral response (SVR) 0.48 [0.11–2.06] 0.32 0.71 [0.21–2.32] 0.56
Cirrhosis 0.99 [0.50–1.95] 0.97
Diabetes 1.51 [0.54–4.21] 0.43
1: antiretroviral treatment
2: for a difference of 50 cells/mm3
https://doi.org/10.1371/journal.pone.0208657.t003
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Conversely, despite a long history of chronic HCV infection in our patients (median 14 (8–22)
years), no association was observed with HCV-related variables such as HCV transmission
group, duration of HCV infection, cirrhosis, HCV genotype, HCV viral load or SVR.
Many questions regarding the relationship between HCV replication and non HCV-liver
related cancers remain unanswered. It is well established that HCV replication is observed in
both T and B lymphocyte subsets and is associated with chronic immune activation [15]. Large
cohort studies have shown that chronic HCV infection is associated with an elevated risk of
developing lung, pancreatic, oropharyngeal, thyroid, skin or breast cancers in HCV mono-
infected patients [7,9–11,16]. HCV eradication following anti-HCV treatment has been associ-
ated with a high proportion of complete or partial response of B cell non-Hodgkin lymphoma
both in HCV mono-infected patients and in HIV/HCV co-infected patients, supporting the
role of chronic antigenic stimulation by HCV on lymphoma genesis [17,18]. Furthermore,
HCV infection has also been associated with a higher risk of mortality from esophagus, pros-
tate and thyroid cancers in HCV mono-infected patients with detectable HCV RNA, as com-
pared to HCV mono-infected patients with undetectable HCV RNA [9]. In a retrospective
Spanish study, HIV/HCV-coinfected patients had a higher cumulative incidence of NANL
cancer than HIV-monoinfected patients (adjusted HR 1.26) [19]. However, in a study involv-
ing 1625 HIV/HCV-coinfected patients who were followed up for a median of five years after
the end of treatment with interferon plus ribavirin, SVR was not associated with a reduced
hazard of NANL related cancers [20]. In our study, patients with SVR tended to have a lower
risk of NANL related cancer (aHR 0.71, 95% CI 0.21–2.32, p = 0.56) but the association was
not statistically significant.
Impaired immunity is associated with a higher risk of EBV or HPV related cancer. In HIV
mono-infected patients, the most frequent non-AIDS-related cancers are oncogenic virus
associated malignancies such as EBV and HPV, and low CD4 counts have been associated
with a higher risk of these cancers [2,6,21–23]. HCV infection has also been associated with a
higher risk of anal cancer in non HIV patients [24]. Furthermore, a higher prevalence of high
risk HPV has been observed among non-HIV female liver transplant candidates with HCV
chronic infection compared to women without HCV infection [25]. The higher risk of HPV
related cancers in HCV mono- infected patients could be related in part to impaired immunity
due to cirrhosis. Indeed, cirrhosis has been associated with decreased monocyte function,
altered natural killer activity and lectin-induced proliferation of T lymphocytes [25,26]. In our
study, the role of HPV was probable in 15% of the cancers (anal cancer, tonsil cancer, tongue
cancer and penile cancer). We found no association between a nadir CD4 cell count below
200/mm3, low current CD4 count or cirrhosis, and the occurrence of NANL related cancers.
However, we could not evaluate the duration of CD4 count below 200/mm3 for most of our
patients.
Surprisingly, tobacco or alcohol consumption, which are both well known risk factors for
some cancers, such as oropharyngeal and lung cancers, were not found to be associated with
the occurrence of NANL related cancers in our study, probably because these cancers were not
specifically evaluated [27]. Low CD4/CD8 ratio has also been associated with non-AIDS defin-
ing cancer in patients on antiretroviral therapy but no such association was observed in our
study [28].
The major strength of this large study (1391 patients followed in 28 hospitals throughout
France) is that we adjusted for most factors (including socio-behavioral characteristics) poten-
tially associated with NANL related cancers in patients with long duration of both HIV and
HCV infection. The main limitation of our study is that despite a median follow-up of 5 years
(IQR, 1.9–7.5 years), few cases of NANL related cancers occurred. Therefore, the non-signifi-
cant results observed in our study, for example regarding the impact of CD4 cell count nadir,
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duration of HCV infection and SVR, could be related to a lack of power. Consequently, our
results need to be confirmed in larger cohorts with longer follow-up.
In conclusion, age and the time since HIV diagnosis were the only factor found to be associ-
ated with an increased risk of NANL related cancers in this study. In contrast, no association
was observed with any HCV-related variables. Since a marked increase in the rate of viral
responses is observed in HIV/HCV coinfected patients receiving direct-acting anti-HCV
drugs, further research is needed to determine whether suppression of HCV replication would
have an impact on occurrence of some of these NANL related cancers.
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